Friday morning, we suggested that Merck had a busy week.

But it was still busy Friday afternoon when Philly guy and Merck Chief Executive Officer Kenneth Frazier was named to lead the Penn State board of trustees' investigation of how former assistant football coach Jerry Sandusky was allegedly sexually assaulting boys over many years, sometimes at Penn State facilities or Penn State football road trips, and university supervisors did little or nothing to stop him.

Pennsylvania Attorney General Linda Kelly announced the charges Saturday, including those of two school officials. The grand jury report is here. Sandusky has denied the charges, as have the two school officials. Penn State football coach Joe Paterno, who was not charged, was fired Wednesday night.

Frazier is a Penn State graduate and a member of the board.

Before all that, Frazier was the son of a Philadelphia janitor and Northeast High School graduate. The Inquirer's Chris Hepp wrote a profile of Frazier when he got the CEO job and that story is here.

The Penn State board of trustees statement said Pennsylvania Education Secretary and ex-officio trustee Ron Tomalis will serve as the vice chair of the committee that "will undertake a full and complete investigation of the circumstances that gave rise to the grand jury report. The committee will be commissioned to determine what failures occurred, who is responsible and what measures are necessary to ensure that this never happens again."

Frazier got his law degree at Harvard. He was Merck's legal counsel during his time with the company and led the legal strategy related to the many Vioxx cases.

"Trustee Frazier has agreed to chair this important committee in this endeavor," Steve Garban, board chairman, said in a statement. "He's experienced, seasoned and will provide the leadership necessary to prevail."

The board of trustees statement is here.

At a Merck meeting for analysts and investors on Thursday, Frazier told the Wall Street Journal, it's been a "terribly sad time" for the university, its alumni and students. "I will say that I think the board took steps they thought were in best interest of the university over the long term......It's a great and principled institution and I believe it has a bright future ahead."

Merck is headquartered in Whitehouse Station, N.J., and has operation in North Wales and West Point.

As for the earlier events in Merck's week, the Associated Press reported that from Thursday's meeting that Merck has eight new products for which it will seek U.S. approval in 2012 or 2013, with hopes that a couple will help with treatment of Alzheimer's disease and hardening of the arteries -- and, thereby generate profit for Merck. The company also announced that it is raising its dividend for the first time since 2004, when the Vioxx disaster hit. The dividend goes up 4 cents to 42 cents.

However, while Frazier might be wearing an investigative hat in his board of trustees role, his company is on the defensive side again, according to filings with the Security and Exchange Commission.

Merck said in a Tuesday filing with the SEC that the company received requests from government investigators for information about the marketing of heart and anti-infective drugs.

The filing says the company received a subpoena from the U.S. Department of Justice requesting information related to the marketing and selling activities around Integrilin and Avelox, from January 2003 to June 2010, in a civil federal health care investigation. Merck says it is cooperating.

The same filing also says Merck received a so-called "Civil Investigative Demand" issued by the Justice Department related to to Inspire Pharmaceuticals, Inc., a company acquired by Merck in May 2011. The CID says Justice is doing a False Claims Act investigation concerning allegations that Inspire submitted false claims to federal health benefits programs (Medicare, Medicaid, etc.) for the drug AzaSite by promoting it for the treatment of indications not approved by the FDA. Again, Merck says it is cooperating.